2017
The interaction between alpha 7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α represents a new antinociceptive signaling pathway in mice
Donvito G, Bagdas D, Toma W, Rahimpour E, Jackson A, Meade JA, AlSharari S, Kulkarni AR, Carroll F, Lichtman AH, Papke RL, Thakur GA, Damaj M. The interaction between alpha 7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α represents a new antinociceptive signaling pathway in mice. Experimental Neurology 2017, 295: 194-201. PMID: 28606623, PMCID: PMC5558428, DOI: 10.1016/j.expneurol.2017.06.014.Peer-Reviewed Original ResearchMeSH KeywordsAlpha7 Nicotinic Acetylcholine ReceptorAmidesAnimalsAzabicyclo CompoundsBenzamidesBridged Bicyclo CompoundsCannabinoid Receptor AntagonistsEthanolaminesFuransMaleMiceMice, Inbred ICRNicotinic AntagonistsNociceptionOxazolesPain MeasurementPalmitic AcidsPPAR alphaReceptor Cross-TalkSignal TransductionTyrosineConceptsPositive allosteric modulatorsAntinociceptive effectNicotinic acetylcholine receptorsΑ7 nAChRsAlpha 7 nicotinic acetylcholine receptorAcetylcholine receptorsNuclear peroxisome proliferator-activated receptorsΑ7 nicotinic acetylcholine receptorPeroxisome proliferator-activated receptorAnalgesic drug developmentProliferator-activated receptorAttenuated formalinAntinociceptive responseFormalin testΑ7 agonistsAntagonist SR144528Nociceptive behaviorTonic painBrain levelsAntagonist GW6471Exogenous administrationΑ7 nicotinicMouse modelCannabinoid CBOrthosteric agonists
2014
Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice
Bagdas D, Muldoon P, Zhu A, Tyndale R, Damaj M. Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. Neuropharmacology 2014, 85: 67-72. PMID: 24859605, PMCID: PMC4106981, DOI: 10.1016/j.neuropharm.2014.05.006.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnxietyAryl Hydrocarbon HydroxylasesConditioning, PsychologicalCytochrome P450 Family 2Disease Models, AnimalDose-Response Relationship, DrugEnzyme InhibitorsHyperalgesiaMaleMecamylamineMethoxsalenMice, Inbred ICRMotor ActivityNicotineNicotinic AgonistsNicotinic AntagonistsRewardSeverity of Illness IndexSubstance Withdrawal SyndromeTobacco Use DisorderConceptsNicotine plasma levelsWithdrawal signsPlasma levelsAdministration of methoxsalenEffect of methoxsalenNicotine dependence behaviorsNicotine replacement therapyChronic nicotine infusionDependence-related behaviorsDrug elimination ratePlace preference testMetabolism of nicotineReward-like propertiesLack of enhancementSpontaneous withdrawalNicotine withdrawalReplacement therapyNicotine preferenceLow doseHigh doseNicotine infusionMouse CYP2A5CPP testActive nicotineNicotine levels
2013
Preclinical evidence for the antihyperalgesic activity of CDP-choline in oxaliplatin-induced neuropathic pain.
Kanat O, Bagdas D, Ozboluk H, Gurun M. Preclinical evidence for the antihyperalgesic activity of CDP-choline in oxaliplatin-induced neuropathic pain. JBUON 2013, 18: 1012-8. PMID: 24344031.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesicsAnimalsCytidine Diphosphate CholineDisease Models, AnimalDose-Response Relationship, DrugGABA-B Receptor AntagonistsHyperalgesiaInjections, IntraventricularMaleNeuralgiaNeurotransmitter Uptake InhibitorsNicotinic AntagonistsOrganoplatinum CompoundsOxaliplatinPain ThresholdRatsRats, Sprague-DawleyTime FactorsConceptsAntihyperalgesic effectNeuropathic painCDP-cholineNonselective muscarinic receptor antagonist atropineNonselective opioid receptor antagonist naloxoneRat paw pressure testReceptor antagonist CGP 35348Muscarinic receptor antagonist atropineNicotinic receptor antagonist mecamylamineOpioid receptor antagonist naloxoneOxaliplatin-induced neuropathic painCholine uptake inhibitor hemicholinium-3Induction of neuropathyAntagonist CGP 35348Paw pressure testGamma-amino butyric acidNicotinic acetylcholine receptorsCGP 35348Neuropatic painMechanical hyperalgesiaAntagonist atropineTime-dependent mannerPreclinical evidenceAntagonist naloxoneAntihyperalgesic activity